AU Patent

AU2010315190A1 — Tryptophan hydroxylase inhibitors for the treatment of cancer

Assigned to Lexicon Pharmaceuticals Inc · Expires 2012-05-10 · 14y expired

What this patent protects

Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.

USPTO Abstract

Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.

Drugs covered by this patent

telotristat-etiprate (TELOTRISTAT ETIPRATE)

Patent Metadata

Patent number: AU2010315190A1
Jurisdiction: AU
Classification: —
Expires: 2012-05-10
Drug substance claim: No
Drug product claim: No
Assignee: Lexicon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.